28.06.2012 | Symbiotics to become regulated fund manager, with reinforced organization

pdfSymbiotics to become regulated fund manager, with reinforced organization

Symbiotics filed for a fund management license in Switzerland in the end of June 2012. This decision came as a continuum of the company's growing business, from a small buy side research boutique to a larger asset manager, one of the leaders in its niche. New developments in the investment fund regulatory frameworks in both Switzerland and the European Union have also reinforced the rationale for this corporate development.

Shareholders of the company met on June 18th to formally modify the status of the company to this end, including asset management at the core of the company's activities and widening the investment universe to include emerging, sustainable and social investments in a broader sense, still with a specific focus on small enterprise development. The group's affiliates in Geneva (Symbiotics Research & Advisory S.A., Symbiotics Asset Management S.A. and Symbiotics Brokerage & Structuring S.A.) were also merged into a single legal entity, whose name was modified from "Symbiotics S.A. Information, Consulting & Services" to "Symbiotics S.A.". All activities, duties and obligations of the affiliated companies, or their mother company, pertain today to the succession company, Symbiotics S.A., and all affiliates abroad in Mexico, Singapore and South Africa remain unchanged.

The company is now organized in three profit centers or business units: Research & Advisory, Asset Management and Investor Relations, and two back office units: Corporate Services as well as the newly constituted Risk & Compliance unit. Yvan Renaud, with the firm since 2006 and previously head of operations, has been appointed director of the Risk & Compliance unit.

Roland Dominicé, CEO, comments: "We're very pleased to transform into a regulated entity, which will reinforce the solidity and credibility of our firm, moreover in a changing financial industry, for the benefit all of our stakeholders: our clients, partners, staff and shareholders. It will also enable us to deploy the strategic goals which we've set for ourselves in the coming years." The transformation process is expected to take 6 to 12 months.

 

For more information:

Claire Dorey, Communication Officer

 

Tel. +41 22 338 15 40

claire.dorey@symbioticsgroup.com

www.symbioticsgroup.com

 

Legal Disclaimer: The collective investment schemes (the “Investment Products”) referred to on the following pages have not been approved for public distribution in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) pursuant to the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations. Accordingly, units of such Investment Products and information, documents or material pertaining to these Investment Products on the following pages may only be distributed in or from Switzerland to qualified investors (as such term is defined in the CISA and its implementing regulations). The information, documents and material pertaining to these Investment Products on the following pages are strictly confidential and do not constitute an offer to any other person or entity than Swiss qualified investors and may only be used by those qualified investors who have accessed them. They may not be copied, used by, distributed or made available to any other person.

Similarly the information on the following pages is only intended to be viewed by persons who fall outside the scope of any law that seeks to regulate financial promotions in the country of your residence or in the country in which the content of this website is being viewed.

If you are uncertain about your position under the laws of the country in which the content of this website is being viewed then you should seek clarification by obtaining legal advice from a lawyer practicing in the country of your residence or in the country in which the content of this website is being viewed before accessing this website.

The information, documents and material contained in the following pages are not warranted to be accurate, complete, or timely. More specifically, Symbiotics SA may not be held responsible for and does not take any position with respect to the accuracy and completeness of information in the following pages.

Agree    Disagree